Alphamab Oncology (HKG:9966) expects a profit of at least 150 million yuan for the year 2024, compared with a loss of around 210.6 million yuan a year prior, a Tuesday filing with the Hong Kong bourse said.
The drugmaker attributed the anticipated turnaround to profit mainly to three license collaborations and sales revenue.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。